Pathos AI
Pathos: AI and big data-driven platform streamlining end-to-end drug discovery and development.
Founded
2020Pathos: AI and big data-driven platform streamlining end-to-end drug discovery and development.
Pathos AI is a clinical-stage biotechnology company dedicated to revolutionizing drug development through its AI-driven platform. The company's mission is to streamline the end-to-end process of designing and developing novel therapeutics, thereby reducing the time and cost associated with bringing new medications to market. Pathos leverages big data, advanced AI technologies, and its proprietary PathOS Platform™ to identify and validate drug targets, explore novel concepts, and advance breakthrough therapies. The platform is particularly focused on oncology, utilizing vast amounts of real-world and patient-derived genomic data.
Pathos AI has made significant strides in the biotechnology field by forming strategic partnerships with leading biopharmaceutical companies. These collaborations have enabled the company to apply its AI-driven insights to real-world drug development challenges, resulting in more precise and effective treatments. The impact of Pathos AI's technology is evident in its ability to uncover compelling biological targets that traditional methods might overlook, thereby accelerating the discovery of innovative therapies for complex diseases.
Companies similar to Pathos AI include Zephyr AI, PathDrugomics, PathAI and BioAI Health.
Pathos AI was founded in 2020.
Pathos AI's headquarters is located in Chicago, IL, US.
Pathos AI's most recent funding round was for $20M (USD) in March 2023.
As of Mar 2, 2023, Pathos AI has raised a total of $20M (USD).
Pathos AI has 3 employees as of Feb 5, 2024.
PathAI
